Econlib Resources
|
TRACKBACKS (3 to date)
TrackBack URL: http://econlog.econlib.org/mt/mt-tb.cgi/147
The author at The Club for Growth Blog in a related article titled Friday's Daily News writes:
COMMENTS (9 to date)
quan nguyen writes:
I do not see any need to "replace medical license requirements". We currently have the "reputation system" in place. As I recall, recent reports show that around 40% of patients use alternative medicine in the past 12 months. Supplement market is huge for most common ailments or prevention. Hospitals in India, Singapore, China, South American, and Southeast Asian countries have been attracting paying foreign (including American) patients in increasing large number due to their high standards and low costs. Thus, medical licensees in this country are judged as a group like everybody else on reputation. Take away the licensing authority of the medical societies, whom the public rely on? Consumer Reports or Ralph Nader's organization? "This is the pilot speaking. We have a medical emergency onboard. Is there a five-star rated health practitioner aboard? no license needed of course." Posted October 19, 2004 10:22 PM
Lawrance George Lux writes:
I advocate a Bonding process which replaces Malpractice insurance, as I am sure Underwriters will do the best job of performance appraisal. I suggest a minimum bond of $5m. Failure of appropriate Bond gaining an individual ten years in prison without benefit of Probation or parole. Punitive damages will be limited to the size of the Bond, though the Individual's income can be garnished to pay for remedial costs. The prior scope of your Post needs examination. The only effective manner for Drug Patent registration may be a two-tier system, where a awarded, stipulated Patent royalty is granted until registered R&D costs are recouped, then a much lower Patent royalty is granted thereafter--posssibly only minescule in amount for perpetuaty. The incentive remains, but the amounts allowed are regulated. lgl Posted October 20, 2004 12:22 PM
Bernard Yomtov writes:
And how, exactly, is the FDA going to assign these letter grades without clinical trials? Frankly this is market-worship at its worst. Information is not free, and relying on a "reputation system" for medical practitioners or drugs is likely to have huge costs. Posted October 20, 2004 8:51 PM
J Thomas writes:
Thank you for bringing these facts to light. Posted October 21, 2004 6:59 AM
Bernard Yomtov writes:
Quan Nguyen raises a serious point that I overlooked in my previous comment. A reputation system depends on consumers making informed choices. In an emergency, how is the patient going to make such a choice? Doesn't there have to be a minimum standard that practitioners must meet, and isn't that what a licensing system aims at? Posted October 21, 2004 11:33 AM
Kevin Carson writes:
Portraying Big Pharma, the poster child for state capitalism and corporate welfare if their ever was one, as a victim of "anti-market" bias takes chutzpah. Do away with their patents, the half of their R&D funding that's carried out on the taxpayer's teat, and their reliance on the FDA and the licensing boards' "standards of practice" to suppress competition, and I'll take that seriously. The drug industry has about as much to do with the "free market" as ADM's Dwayne Andreas, who said "The competitor is our friend; the customer is our enemy." Posted October 21, 2004 2:16 PM
spencer writes:
The entire thing about importing drugs from Canada is a tempest in a teapot that does not meet the basic test of common sense. Importing drugs from Canada is taking advantage of a loop hole. As long as a few people do it they can get away with exploiting the loophole. But once a significant number of people try to import drugs from canada the system will break down. Put the numbers for Canada vs the USA in perspective and you will see that the issue is not worth your time thinking about. Posted October 22, 2004 1:07 PM
Ken writes:
"And how, exactly, is the FDA going to assign these letter grades without clinical trials? Frankly this is market-worship at its worst. Information is not free, and relying on a "reputation system" for medical practitioners or drugs is likely to have huge costs." Having a 10-15 year ban on new drugs also has huge costs. There are situations where people will need to take drugs even if they haven't been through the whole testing process - is it right for the FDA to deny them their shot at survival and seal their doom? I think not. "A reputation system depends on consumers making informed choices. In an emergency, how is the patient going to make such a choice? Doesn't there have to be a minimum standard that practitioners must meet, and isn't that what a licensing system aims at? " Well, a reputation system, just like a licensing system, only requires someone to make informed choices and prove themselves trustworthy, and not necessarily the people having the emergency. The only difference between a reputation system and a licensing board is that the private operators lack the power to make their word into law, and thus must prove their judgements trustworthy. And long before you have an emergency, you will have plenty of opportunity to decide whose judgement you will accept. Posted October 23, 2004 9:55 AM
Ralph Lee writes:
And how do you propose to measure the quality of a practitioner? I'm fairly ignorant of health economics, but if you revoke or "downgrade" a medical practitioner for each "error", it would seem like providers of health care would see incentives to perform only risk-free procedures, thus starving the market for procedures that can possibly give rise to such penalties. In addition, grading would seem to only punish those who have wronged (intentionally or not), instead of rewarding those who do well. Posted October 25, 2004 4:11 PM
Comments for this entry
have been closed
|
||||||||
|
|
Blogging software: Powered by Movable Type 4.2.1.
Pictures courtesy of the authors. All opinions expressed on EconLog reflect those of the author or individual commenters, and do not necessarily represent the views or positions of the Library of Economics and Liberty (Econlib) website or its owner, Liberty Fund, Inc.
The cuneiform inscription in the Liberty Fund logo is the
earliest-known written appearance of the word
"freedom" (amagi), or "liberty." It
is taken from a clay document written about 2300 B.C. in the Sumerian city-state of Lagash.
|
||||||||